CM082
Asset
Multitargeted tyrosine kinase inhibitor targeting VEGFR and PDGFR receptors
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- PDGFRB
- 2
- Indications
- 642
- Trials
- 1
- Developer
Indications
2Renal cell cancer metastatic
Phase 3, Unknown, NCT03095040, clinicaltrials.gov, 7 Oct 2026
Renal cell carcinoma recurrent
Phase 1, Unknown, NCT02577458, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials642
- Evidence for its targets3
- Competitors6
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 4 sources